MassHealth covers testosterone replacement therapy — with prior authorization — for men with documented hypogonadism. It does not cover testosterone when the sole indication is erectile dysfunction or "sexual dysfunction." That distinction is the source of most of the internet confusion. If two morning total testosterone measurements come back below 300 ng/dL and your physician documents an appropriate diagnosis (primary hypogonadism, hypogonadotropic hypogonadism, gender dysphoria, or delayed puberty), MassHealth will approve testosterone cypionate, enanthate, gels, or patches through the retail pharmacy benefit. If the only indication in your chart is ED, MassHealth will deny the prior authorization.
What MassHealth actually covers
The MassHealth Drug List includes testosterone across every common formulation — testosterone cypionate injection, testosterone enanthate injection, 1% and 1.62% topical gels (Androgel and equivalents), Vogelxo, Testim, Androderm patches, and oral formulations like Jatenzo, Kyzatrex, and Tlando. Every one of these products requires prior authorization (marked "PA" on the drug list), but every one of them is a covered benefit for the right indication.
The four covered indications, per the MassHealth Drug List's Androgens therapeutic class page, are:
- Primary hypogonadism (testicular failure — congenital or acquired)
- Hypogonadotropic hypogonadism (pituitary or hypothalamic origin)
- Gender dysphoria or therapy after gender reassignment surgery
- Delayed puberty (adolescents 14–17 with additional pediatric-endocrinologist criteria)
For adult men with hypogonadism — which is what most men searching for TRT actually have — the pathway is documented and reproducible. It just requires a MA-licensed prescriber willing to work through the prior authorization process, and lab work that meets the criteria.
What MassHealth doesn't cover — and the source of the confusion
Two separate MassHealth documents create the widespread perception that "MassHealth doesn't cover TRT":
- The Erectile Dysfunction coverage policy lists "exogenous testosterone replacement therapy" under "non-coverage" — described as "experimental and investigational" — but the full context on that page is that the entire policy governs treatment for erectile dysfunction. If ED is the diagnosis, MassHealth's position is that testosterone is not the right treatment. That is a narrow, indication-specific ruling — not a blanket exclusion.
- The drug exclusions rule at 130 CMR 406.413(B)(6) says MassHealth does not pay for "any drugs when used for the treatment of sexual dysfunction." Again, indication-specific. If sexual dysfunction is the sole diagnosis on the chart, testosterone gets excluded like sildenafil and tadalafil do.
Men who search "does MassHealth cover TRT" often see the "experimental and investigational" language and conclude testosterone is off-limits under MassHealth. That is not what the policy says. The policy says testosterone is off-limits as an ED treatment. When the treating physician documents hypogonadism as the primary diagnosis and orders confirmatory bloodwork, testosterone is a covered benefit under the same drug list every MassHealth member uses.
This distinction matters for how you talk to your prescriber. If your primary complaint is low libido or erectile problems, and your bloodwork also happens to show low testosterone, the diagnosis your physician documents needs to be hypogonadism — with sexual symptoms listed as manifestations of that hypogonadism — rather than "erectile dysfunction, low testosterone." The distinction is not cosmetic. It's the difference between an approved PA and a denied PA.
The prior authorization criteria, in detail
The MassHealth prior authorization criteria for testosterone products (across cypionate, enanthate, gels, patches, and oral formulations) are consistent and specific:
| Criterion | Requirement |
|---|---|
| Diagnosis | Primary hypogonadism, hypogonadotropic hypogonadism, gender dysphoria, or delayed puberty (with age criteria) |
| Lab confirmation | Two morning total testosterone measurements below 300 ng/dL |
| Lab timing | Two labs drawn no more than three months apart |
| Lab recency | Both labs drawn within one year of the prior authorization request |
| Prescriber | Licensed in Massachusetts; standard practitioner (pediatric endocrinologist required only for delayed puberty) |
| Initial approval duration | 12 months (6 months for delayed puberty) |
| Reauthorization | Prescriber attests to positive response; renewed annually |
Sources: MassHealth Drug List — Androgens, Mass General Brigham Health Plan — MassHealth Androgen PA (June 2025).
SmartPA — the auto-processing pathway most patients don't know about
Here's the piece almost nobody writes about clearly: MassHealth uses a system called SmartPA that can automatically process a testosterone refill at the pharmacy counter without a fresh prior authorization if the member's MassHealth claims history already supports the diagnosis.
Specifically, per the MassHealth Drug List, testosterone cypionate, testosterone enanthate, and multiple gel and packet formulations "will usually process at the pharmacy without a PA request if the member has a history of MassHealth medical claims for primary hypogonadism or hypogonadotropic hypogonadism and a history of paid MassHealth pharmacy claims of the requested agent for at least 90 out of the last 120 days."
Translation: if your MassHealth record already documents hypogonadism and you've been filling testosterone through MassHealth for at least three months out of the previous four, your refills should run through the pharmacy adjudication system automatically — no re-submitting paperwork, no faxing your labs, no follow-up call from the PBM.
If you're switching from a different MassHealth-billing prescriber to Aurafil or vice versa, make sure your medical records reflect the hypogonadism diagnosis and that pharmacy claims history transfers. The SmartPA lookup runs against your MassHealth claims history — not the prescriber's — so a well-documented history from a prior MA-licensed provider carries over.
Which testosterone products MassHealth prefers
MassHealth generally prefers the least expensive effective option. First-line products — those most likely to be approved without extensive step-therapy justification — are:
- Testosterone cypionate intramuscular injection (generic Depo-Testosterone)
- Testosterone enanthate intramuscular injection
- Testosterone 1% topical gel (generic Androgel/Testim)
Products that require additional step-therapy documentation — meaning the member has to have tried and failed first-line options first — include Xyosted, Jatenzo, Kyzatrex, Tlando, Aveed, and Natesto. This is not because they don't work; it's because they cost substantially more per month of therapy, and MassHealth's approach is standard payer economics.
For most adult men on TRT in Massachusetts, testosterone cypionate injection every seven days is the exact regimen the guidelines call first-line — and it happens to also be the regimen MassHealth prefers. If a prescriber is starting your therapy with a compounded oral or a specialty auto-injector, ask why. The answer might be legitimate; more often it's a clinic that hasn't done the work to submit the PA for the standard-of-care option.
Where Aurafil Health fits in the MassHealth picture
Aurafil Health is a cash-pay, membership-model telehealth practice. We are not currently a MassHealth provider. That means Aurafil membership fees and Aurafil-arranged medication cannot be billed to MassHealth for reimbursement.
Here's why cash-pay membership works for many MassHealth-eligible men anyway:
- Speed to eligibility. A MassHealth PA cycle for testosterone can take 3–8 weeks between the initial specialist referral, the two lab draws, the PA submission, and the pharmacy filling. Aurafil moves from eligibility check to first injection in 7–14 days.
- All-in cost transparency. Aurafil is $297 for your first three months (consult, testosterone, syringes, all follow-up) and $99/month after. That includes bloodwork ordering — labs are billed direct to you (often <$100) so you see exactly what you're paying. For a member without a MassHealth-friendly PCP willing to run the PA, the math often works in Aurafil's favor.
- No PA denial risk. Because Aurafil doesn't bill insurance, there's no PA to be denied. Your prescriber sees your labs, discusses risks, and prescribes if appropriate.
- Coordination if you want to try MassHealth first. If cost is your only barrier and MassHealth coverage is essential, we can help you understand what to bring to your PCP or an in-person MA endocrinologist to build the PA package. We'd rather help you get affordable care through your existing benefits than take money you don't need to spend.
For members whose MassHealth plan already documents hypogonadism and who are filling testosterone through their plan pharmacy today, MassHealth is usually the right path. For members who've been told "your levels aren't low enough" or whose PCP has declined to work up hypogonadism, Aurafil offers a second opinion from a MA-licensed physician with a faster workup.
Not sure whether MassHealth is your best path?
Book a free eligibility check with an Aurafil advisor. We'll help you understand both options — MassHealth and cash-pay — and pick the one that actually fits your situation.
Check eligibilityCommon MassHealth-and-TRT misconceptions
My PCP told me MassHealth doesn't cover testosterone. Is that true?
Not in the general case. MassHealth covers testosterone for hypogonadism with prior authorization. What your PCP may have meant is that they aren't going to submit the PA — usually because they aren't confident in interpreting borderline testosterone bloodwork, or because their practice doesn't have the pharmacy authorization workflow set up. That's a workflow issue, not a coverage issue. A MA-licensed prescriber willing to do the paperwork can get the PA approved.
Does MassHealth cover the bloodwork I need for TRT?
Yes. Morning total testosterone, LH, FSH, prolactin, and other endocrine markers are covered lab tests under MassHealth when ordered by a MA-licensed prescriber for a covered indication. The two morning total testosterone measurements required for the PA are themselves covered draws.
My testosterone came back at 285 ng/dL. Is that low enough for MassHealth?
Below the 300 ng/dL threshold that MassHealth uses for hypogonadism confirmation — but a single draw isn't enough. The rule is two morning draws (7–10 AM, fasting) no more than three months apart, both below 300 ng/dL. If your second draw is 310, you don't qualify under the MassHealth criteria as currently written even if your symptoms are consistent with hypogonadism. This is one place where the MassHealth criteria are more restrictive than the Endocrine Society's — see the bloodwork guide for detail on where the numbers come from.
Does MassHealth cover HCG or enclomiphene for younger men who want to preserve fertility?
HCG is not listed as a covered product on the MassHealth Drug List for testosterone-preservation purposes and is generally denied for that indication. Enclomiphene is available generically but is not routinely approved under MassHealth for hypogonadism as a first-line option. For younger men (under 40) who want to preserve fertility, cash-pay pathways through Aurafil or another MA-licensed practice are typically faster and more likely to result in a fertility-preserving protocol. See our fertility guide.
Can I use MassHealth and Aurafil at the same time?
Yes — many patients do. MassHealth can cover your labs and, in principle, your medication if the PA is submitted and approved. Aurafil can be your physician relationship and care team. Since Aurafil doesn't bill MassHealth, your Aurafil membership fee is out-of-pocket, but your medication cost could potentially route through MassHealth if a MassHealth-participating pharmacy is willing to fill an Aurafil prescription — the practicalities of coordinating that are worth a conversation before assuming it will work.
Does the MassHealth PA process work differently if my ACO or MCO has a different pharmacy benefit manager?
MassHealth uses a Unified Pharmacy Policy that applies across most Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) — the same criteria for testosterone apply whether you're a Fee-for-Service MassHealth member, a WellSense member, a Mass General Brigham Health Plan member, or a Tufts Health Together member. There are edge cases where MCO-specific policies apply; if you get a denial that doesn't match the MassHealth Drug List criteria, check with your MCO's pharmacy benefits page.
Keep reading
Sources & citations
- MassHealth Drug List — Androgens Therapeutic Class
- MassHealth Drug List (A–Z)
- MassHealth Erectile Dysfunction Coverage Policy
- 130 CMR § 406.413 — Limitations on Coverage of Drugs
- Mass General Brigham Health Plan — MassHealth Androgen PA (June 2025)
- Endocrine Society Clinical Practice Guideline: Testosterone Therapy in Men With Hypogonadism (JCEM 2018)
- AUA: Evaluation and Management of Testosterone Deficiency (2018)